UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. UCB will pay $650 million upfront and up to $500 million in potential […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!